Catalog No.
VVV19901
Species reactivity
Dengue virus type 2 (DENV-2)
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Target
E glycoprotein, Envelope protein E, EDIII
Concentration
2.43 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
W5RZ25,P18356
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0124
Darunavir inhibits dengue virus replication by targeting the hydrophobic pocket of the envelope protein., PMID:40024350
Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis., PMID:39085250
Liang-Ge-San inhibits dengue virus serotype 2 infection by reducing caveolin1-induced cytoplasmic heat shock protein 70 translocation into the plasma membrane., PMID:37506573
N-Butanol Extract of Glycyrrhizae Radix et Rhizoma Inhibits Dengue Virus through Targeting Envelope Protein., PMID:37259408
Quercetin attenuates viral infections by interacting with target proteins and linked genes in chemicobiological models., PMID:36119653
Sulfated β-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis., PMID:35533778
Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo., PMID:33299049
Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo., PMID:32517029
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868
Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection., PMID:31636070
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852
In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2., PMID:28400226
Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees., PMID:26889737
Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention., PMID:24550728
Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing., PMID:24335303
Dengue virus type 2: protein binding and active replication in human central nervous system cells., PMID:24302878
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection., PMID:23785205
Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection., PMID:23545366
Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli., PMID:22420529
Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses., PMID:21419774
Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia., PMID:20651932
Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines., PMID:18160621
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes., PMID:17881453
Infectious clone construction of dengue virus type 2, strain Jamaican 1409, and characterization of a conditional E6 mutation., PMID:16847122
For research use only. Not for human or drug use.
